Beacon Pointe Advisors LLC Buys New Shares in United Therapeutics Corporation $UTHR

Key Points

• Beacon Pointe Advisors acquired 2,389 United Therapeutics shares worth approximately $1.29 million in the second quarter. Institutional investors collectively own 94.08% of UTHR.
• Company insiders sold 404,575 shares valued at approximately $216.7 million over the past three months, including sizable sales by the CEO and CFO.
• Analysts maintain a “Moderate Buy” consensus with a $646 price target. United Therapeutics recently exceeded quarterly EPS expectations, reporting $7.27 versus the $6.86 consensus, although revenue declined 1.9% year over year.

Beacon Pointe Advisors LLC acquired a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 2,389 shares of the biotechnology company's stock, valued at approximately $1,294,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in UTHR. Fiduciary Financial Advisors bought a new stake in shares of United Therapeutics during the second quarter worth about $30,000. WealthCollab LLC increased its holdings in United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 38 shares in the last quarter. Rakuten Securities Inc. increased its holdings in United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 46 shares in the last quarter. Entrust Financial LLC purchased a new stake in shares of United Therapeutics in the fourth quarter worth approximately $31,000. Finally, Caitlin John LLC bought a new position in shares of United Therapeutics in the second quarter valued at approximately $37,000. Institutional investors own 94.08% of the company's stock.

Insider Activity at United Therapeutics

In related news, CEO Martine A. Rothblatt sold 9,500 shares of the business's stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $547.61, for a total transaction of $5,202,295.00. Following the transaction, the chief executive officer owned 40,513 shares in the company, valued at $22,185,323.93. The trade was a 19.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO James Edgemond sold 10,000 shares of the stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $546.28, for a total value of $5,462,800.00. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares of the company's stock, valued at $10,311,581.28. This represents a 34.63% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 404,575 shares of company stock worth $216,652,640 over the last three months. Insiders own 8.60% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Bank of America lowered their target price on shares of United Therapeutics from $620.00 to $613.00 and set a "neutral" rating for the company in a report on Friday, July 10th. Royal Bank Of Canada cut their price target on shares of United Therapeutics from $704.00 to $677.00 and set an "outperform" rating on the stock in a report on Thursday, August 6th. JPMorgan Chase & Co. upped their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an "overweight" rating in a research report on Thursday, July 23rd. Wells Fargo & Company upgraded shares of United Therapeutics from an "equal weight" rating to an "overweight" rating and increased their price objective for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. Finally, Weiss Ratings cut shares of United Therapeutics from a "buy (b)" rating to a "buy (b-)" rating in a research report on Thursday. Eleven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $646.00.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR opened at $515.46 on Monday. The stock's 50-day moving average is $530.46 and its 200 day moving average is $539.16. The stock has a market cap of $22.11 billion, a price-to-earnings ratio of 18.44, a P/E/G ratio of 1.75 and a beta of 0.59. United Therapeutics Corporation has a 1-year low of $303.08 and a 1-year high of $609.35.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.86 by $0.41. The business had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company's revenue was down 1.9% on a year-over-year basis. During the same period in the prior year, the business posted $6.41 earnings per share. On average, analysts forecast that United Therapeutics Corporation will post 26.33 EPS for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source